- The Asia-Pacific hepatitis delta virus (HDV) infection market is experiencing significant growth due to increasing awareness, improved diagnostic capabilities, and enhanced access to healthcare services across developing countries in the region
- The growing burden of liver-related diseases, rising healthcare expenditures, and government-led hepatitis elimination programs are the primary factors driving market expansion in Asia-Pacific
- China dominated the Asia-Pacific hepatitis delta virus (HDV) infection market with the largest revenue share of 36.84% in 2024, driven by its large patient population, government-supported hepatitis elimination programs, and increased adoption of advanced diagnostic and therapeutic solutions
- India is expected to witness the fastest-growing CAGR of 6.9% in the Asia-Pacific hepatitis delta virus (HDV) infection market during the forecast period, fueled by rising healthcare awareness, expanding diagnostic infrastructure, and growing government and private sector investments in infectious disease management
- The Parenteral route of administration segment dominated the Asia-Pacific HDV market with a share of 66.5% in 2024, supported by the widespread use of injectable pegylated interferon as the standard treatment, ensuring effective viral suppression and alignment with established clinical protocols
